Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J., … Desjardins, A. (n.d.). Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. In Neuro-Oncology (Vol. 17). San Antonio, TX: Oxford University Press (OUP). https://doi.org/10.1093/neuonc/nov206.13

Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro-Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.

Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, et al. Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. In: Neuro-Oncology. Oxford University Press (OUP);

Weant, Mallika, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” Neuro-Oncology, vol. 17, no. Suppl. 5, abstr. ATCT-13, Oxford University Press (OUP). Manual, doi:10.1093/neuonc/nov206.13.

Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Neuro-Oncology. Oxford University Press (OUP);